Prospective Evaluation of Infants With Spinal Muscular Atrophy:
study id #: NCT02831296
condition: Spinal Muscular Atrophy
status: Recruiting
purpose:SPOT SMA is a prospective NIH-supported clinical study targeting pre-symptomatic or recently diagnosed infants and children with Spinal Muscular Atrophy (SMA) types 1, 2, or 3 and their healthy control siblings less than 36 months of age at the time of study enrollment. The main objective of the study is to prospectively collect longitudinal clinical outcomes and provide counseling and education to parents of newly diagnosed children. The study will assess the impact of current standard of care management paradigms and interventions on health outcomes in newly diagnosed SMA infants and children with type 1, 2 or 3 and age appropriate controls. There is no investigational drug and no specific intervention in this study. Rather, the investigators will document outcomes related to current therapies provided to participating subjects, and will educate participants about possible clinical trial opportunities.
results: https://clinicaltrials.gov/ct2/show/results/NCT02831296
last updated: February 04, 2022
-
Targeted NGS Seen as Best When Screening for SMA and Its CarriersTargeted next generation sequencing (NGS...
-
Baby Among the First to Receive Gene Therapy for Spinal Muscular Atrophy After FDA Approvalhttps://www.youtube.com/watch?v=adc6vztu...
-
Spinal Muscular Atrophy: Types and GeneticsSpinal Muscular Atrophy (SMA)SMA is a ra...
-
SMA Type 1 – Looking After Your Child Who Has Had a Recent DiagnosisThe aim of everyone involved in your chi...
-
Generation of DMBi002-A Human Induced Pluripotent Stem Cell Line From Patient With Spinal Muscular Atrophy Type 3Spinal Muscular Atrophy (SMA) is a genet...
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022Scholar Rock, a clinical-stage biopharma...
-
SMA Type 2 – Looking After Your Child Who Has Had a Recent DiagnosisOne of the first questions many families...